

10/075,918

- 3 -

Barvian et al.

**AMENDMENT TO THE CLAIMS**



The following listing of claims will replace all prior versions and listings of claims in the application.

**Listing of claims:**

**Claims 1 and 2 (Canceled).**

**Claim 3 (Currently amended).**

A method for treating [breast carcinoma,] rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from [breast carcinoma,] rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula III



III

wherein:

10/075,918

- 4 -

Barvian et al.

$R^1$ ,  $R^2$ , and  $R^3$  independently are hydrogen, halo, hydroxy,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $NO_2$ ,  $NR^4R^5$ , CN, or  $CF_3$ ;

$R^4$  and  $R^5$  independently are  $(CH_2)_n$  heterocyclyl,  $(CH_2)_n$  heteroaryl, or  $R^4$  and  $R^5$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;


$n$  is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof.

**Claims 4 and 5 (Cancelled).**

**Claim 6 (Currently amended).**

A method for treating [breast carcinoma,] rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from [breast carcinoma,] rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula VI



VI

or a pharmaceutically acceptable salt thereof,

wherein:

$R^1$ ,  $R^2$ , and  $R^3$  independently are hydrogen, halo, hydroxy,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $NO_2$ ,  $NR^4R^5$ , CN, or  $CF_3$ ;

10/075,918

- 5 -

Barvian et al.

$R^4$  and  $R^5$  independently are  $(CH_2)_n$  heterocyclyl,  $(CH_2)_n$  heteroaryl, or

$R^4$  and  $R^5$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; and

$n$  is an integer from 0 to 6.

**Claim 7 (Currently amended).**

A compound selected from the group consisting of:

Isophthalic acid di-(2,1,3-benzothiadiazol-5-yl) methyl ester;  
4-Methoxy-isophthalic acid dipyridin-4-ylmethyl ester;  
N,N'-Bis-1,3-benzodioxol-5-ylmethyl-4-methoxy-isophthalamide;  
N-1,3-Benzodioxol-5-ylmethyl-N'-furan-2-ylmethyl-isophthalamide;  
4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester;  
N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;  
[N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide];  
N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;  
N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;  
4-Amino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;  
4-Acetylamino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;  
N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;  
[N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide];  
N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-propoxy-isophthalamide; and  
[N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide];  
N1,N3-Bis-2,1,3-benzothiadiazol-5-ylmethyl-4-methoxy-isophthalamide];  
and  
4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester].



**Claims 8 to 17 (Cancelled).**

10/075,918

- 6 -

Barvian et al.

**Claim 18 (Currently amended).** A compound of Formula III



III

wherein:

R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> independently are hydrogen, halo, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, NO<sub>2</sub>, NR<sup>4</sup>R<sup>5</sup>, CN, or CF<sub>3</sub>;

R<sup>4</sup> and R<sup>5</sup> independently are (CH<sub>2</sub>)<sub>n</sub> heterocyclyl, (CH<sub>2</sub>)<sub>n</sub> heteroaryl, or R<sup>4</sup> and R<sup>5</sup> when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof.

10/075,918

- 7 -

Barvian et al.

**Claim 19 (Previously presented).**

A pharmaceutical composition, comprising a compound of Claim 18, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

**Claim 20 (Canceled).**

**Claim 21 (Previously presented).**

A method for treating rheumatoid arthritis, the method comprising administering to a patient suffering from rheumatoid arthritis a therapeutically effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.

**Claim 22 (Previously presented).**

A method for treating osteoarthritis, the method comprising administering to a patient suffering from osteoarthritis a therapeutically effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.

**Claim 23 (Previously presented).**

A method for treating heart failure, the method comprising administering to a patient suffering from heart failure a therapeutically effective amount of a compound of Claim 18, or a pharmaceutically acceptable salt thereof.